These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35307562)
1. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Wicha SG; Mair A; Chiriac U; Frey OR; Fuchs T; Gaasch M; Hagel S; Richter DC; Roberts JA; Röhr AC; Weigand MA; Brinkmann A Int J Antimicrob Agents; 2022 May; 59(5):106572. PubMed ID: 35307562 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study. Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351 [TBL] [Abstract][Full Text] [Related]
3. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Crass RL; Cojutti PG; Pai MP; Pea F Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189 [TBL] [Abstract][Full Text] [Related]
5. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531 [TBL] [Abstract][Full Text] [Related]
7. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002 [TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Cojutti P; Pai MP; Pea F Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia. Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441 [TBL] [Abstract][Full Text] [Related]
10. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880 [TBL] [Abstract][Full Text] [Related]
11. Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia. Takahashi S; Tsuji Y; Kasai H; Ogami C; Kawasuji H; Yamamoto Y; To H J Pharm Sci; 2021 May; 110(5):2295-2300. PubMed ID: 33609520 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Rao GG; Konicki R; Cattaneo D; Alffenaar JW; Marriott DJE; Neely M; Ther Drug Monit; 2020 Feb; 42(1):83-92. PubMed ID: 31652190 [TBL] [Abstract][Full Text] [Related]
14. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients. Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Tsuji Y; Holford NHG; Kasai H; Ogami C; Heo YA; Higashi Y; Mizoguchi A; To H; Yamamoto Y Br J Clin Pharmacol; 2017 Aug; 83(8):1758-1772. PubMed ID: 28186644 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy. Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795 [TBL] [Abstract][Full Text] [Related]
18. Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: A two-centre prospective interventional study. Shi L; Zhang Y; Duan L; Huang L; Li J; Lu J; Zhuang Z; Yuan Y; Feng Z; Sun J; Liu X; Zhou Q; Xue H; Xu J; Tang L Int J Antimicrob Agents; 2023 Aug; 62(2):106881. PubMed ID: 37301313 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of linezolid in critically ill patients. Sazdanovic P; Jankovic SM; Kostic M; Dimitrijevic A; Stefanovic S Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):595-600. PubMed ID: 27020789 [TBL] [Abstract][Full Text] [Related]